Target-Specific Humanized Mouse Models Designed to Enhance Translational Relevance in Oncology Drug Discovery

Customers in the United States can now access selected genOway models through Taconic

 

Taconic provides researchers in the United States with access to a portfolio of genetically humanized mouse models developed by genOway

These models are among the most translational tools available for IO research: they were extensively validated by leading biopharma and CRO companies in IO and supported many IND fillings over the last years. Through a distribution agreement with genOway, Taconic now serves as a U.S. commercial point of contact for model access, quotations, ordering, and customer support.

These target-specific genetically humanized models represent selected human therapeutic targets, primarily within immunocompetent mice, to support mechanism-aligned preclinical research. The portfolio supports evaluation of therapeutics directed against human targets across:

  • T-cell engagers and T-cell-directed multispecifics
  • Immune checkpoint and immunomodulatory pathways
  • Fc-mediated biologics and antibody pharmacology
  • Innate and myeloid immuno-oncology
  • Additional humanized targets relevant to translational research

genOway’s humanized mouse models are designed to enhance translational relevance thanks to a physiological expression of the humanized target in an in vivo system. Supported by extensive validation data generated in-house and with biopharma partners, these models will help you generate robust  preclinical data with a high level of translatability to secure your decisions in the path to the clinic.

Depending on the model and study design, these models can support assessment of therapeutic activity, mechanism of action, pharmacodynamic/pharmacokinetic response, safety-related biology, and biologic disposition.

white mice

genOway’s Humanized Mouse Models Available through Taconic

Browse the target-specific genetically humanized models from genOway available through Taconic. Models are organized by their primary biological or therapeutic application. 

  • Models designated Immediate may be quoted, ordered, and fulfilled now, subject to cohort requirements and availability.
  • Models designated Coming soon are planned for future availability.
  • Models designated as Reference model correspond to first generation models that were extensively used and validated by biopharma companies and will offer the best quality-cost compromise for getting started. 
  • Models designated as Advanced models feature higher levels of humanization for more precise and translatable results.

Select a model name to access technical information, validation data, and additional resources from genOway.

blue mouse graphic

 Swipe to view additional model categories 

T-Cell Engager and T-Cell-Directed Multispecific Models

Models in this category support evaluation of therapeutics that engage, human T-cell populations. The portfolio includes humanized CD3 models for canonical T-cell engager studies and additional models relevant to T-cell-directed multispecific strategies.

ModelAvailabilityGenetic background
Reference models
genO-panhCD3ImmediateC57BL/6N
genO-panhCD3Coming soonBALB/c
genO-hCD3εImmediateC57BL/6N
genO-hCD4ImmediateC57BL/6N
Advanced models
genO-panhCD3/hCD137ImmediateC57BL/6N
genO-panhCD3/hCD28ImmediateC57BL/6N
genO-panhCD3/hPD-1Coming soonC57BL/6N
genO-hCD3ε/hCD28Coming soonC57BL/6N
genO-hCD3ε/hCD28Coming soonC57BL/6N

Immune Checkpoint and Immunomodulatory Models

These models represent inhibitory checkpoints, costimulatory pathways, regulatory T-cell biology, and immunometabolic mechanisms relevant to antitumor immune responses. They can support evaluation of monospecific, combination, bispecific, and other multispecific therapeutic strategies.

ModelAvailabilityGenetic background
Reference models
genO-hPD-1ImmediateC57BL/6N
genO-hVISTAComing soonC57BL/6N
genO-hCD137Coming soonC57BL/6N
genO-hCD137Coming soonBALB/c
genO-hCD28Coming soonC57BL/6N
genO-hCD39Coming soonC57BL/6N
genO-hCD39Coming soonBALB/c
genO-hCTLA-4Coming soonC57BL/6N
genO-hCTLA-4Coming soonBALB/c
genO-hGITRComing soonC57BL/6N
genO-hICOSComing soonC57BL/6N
genO-hOX40Coming soonC57BL/6N
Advanced models
genO-hPD-1/hPD-L1ImmediateC57BL/6N
genO-hPD-1/hCTLA-4Coming soonC57BL/6N
genO-hPD-1/hCTLA-4Coming soonBALB/c
genO-hPD-1/hGITR/hGITRLComing soonC57BL/6N
genO-hPD-1/hLAG3ImmediateC57BL/6N
genO-hPD-1/hICOSComing soonC57BL/6N
genO-hPD-1/hTIM3Coming soonC57BL/6N
genO-hPD-1/hVISTAComing soonC57BL/6N
genO-hOX40/hICOSComing soonC57BL/6N
genO-hCCR8/hCCL1ImmediateC57BL/6N
genO-hGITR/hGITRLImmediateC57BL/6N
genO-hCTLA-4/hLAG3Coming soonC57BL/6N

Fc-Mediated Biologics and PK Models

These models support investigation of human Fc receptor interactions, Fc-dependent effector function, antibody tolerability, FcRn-mediated recycling, albumin binding, and systemic biologic disposition.

ModelAvailabilityGenetic background
Reference models
genO-hSA/hFcRnImmediateC57BL/6N
Advanced models
genO-hSA/hFcRn-RAG1KOComing soonC57BL/6N
genO-hFcγRImmediateC57BL/6N
genO-hFcγR/hFcRnImmediateC57BL/6N
genO-hFcγR/hIgG1Coming soonC57BL/6N
genO-hTFRC/hFcγRComing soonC57BL/6N

Innate and Myeloid Immuno-Oncology Models

These models represent human innate immune sensing and myeloid regulatory pathways relevant to antitumor immunity, inflammatory signaling, and therapeutic mechanism of action.

ModelAvailabilityGenetic background
Reference models
genO-hcGASImmediateC57BL/6N
genO-hSTINGImmediateC57BL/6N
genO-hVISTAComing soonC57BL/6N
Advanced models
genO-hcGAS/hSTINGComing soonC57BL/6N
genO-hCD47/hSIRPαComing soonC57BL/6N
genO-hCD47/hSIRPα/hFcγRComing soonC57BL/6N

Additional Humanized Targets

While the portfolio is primarily focused on immuno-oncology, these models extend access to selected humanized targets relevant to metabolism, inflammation, drug delivery, and other translational research applications.

ModelAvailabilityGenetic background
genO hGLP-1RImmediateC57BL/6N
genO hTFRCImmediateC57BL/6N
genO-hIgE/hFcεR1Coming soonBALB/c
genO hTFRC/hFcγRComing soonC57BL/6N
genO-hTNF-αComing soonC57BL/6J

Access and Support for U.S. Researchers

Customers in the United States can work directly with Taconic to discuss:

  • Model availability
  • Cohort requirements
  • Quotation and ordering
  • Anticipated delivery timing
  • Therapeutic mechanism and model fit
  • Study-specific scientific considerations

Taconic can help researchers identify models aligned with the relevant human target, therapeutic mechanism, and experimental question. Final model selection and study design remain dependent on the objectives and limitations of the individual program.

Frequently Asked Questions

Complete the register interest form on this page and identify the model or models relevant to your program. A Taconic representative will follow up to discuss availability, cohort requirements, timing, and quotation.

Researchers in the United States place orders directly with Taconic. Quotations, ordering, invoicing, and customer support are provided by Taconic, with transactions conducted in U.S. dollars (USD).

Researchers located in the United States should contact Taconic regarding model availability, quotations, ordering, and customer support. Researchers located outside the United States should contact genOway directly or visit the genOway website to determine the appropriate regional contact.

Models designated Immediate are currently available for quotation and ordering through Taconic, subject to cohort requirements, production status, and delivery timing. Models designated Coming soon are planned for future availability and are not yet available for ordering. Customers may register interest to receive follow-up as availability approaches.

Yes. Use the comments field to identify a coming-soon model of interest. This allows Taconic to understand your requirements and provide follow-up as additional models become available.

These models were developed by genOway and are made available to researchers in the United States through Taconic. Taconic serves as aU.S. commercial point of contact for quotations, ordering, customer support, and model access.

Select the model name in any table above to visit the corresponding genOway page. These pages may include model specifications, available validation data, application information, and supporting resources.

Taconic can discuss your therapeutic mechanism, target biology, intended readouts, and study objectives to help identify potentially relevant models. Suitability should be evaluated in the context of the specific experimental question and available supporting evidence.

Yes. Researchers may contact Taconic to discuss therapeutic mechanism, target biology, study design considerations, and model selection before requesting a quotation.

Immediately available models are currently produced by Taconic in the United States. The production location and fulfillment pathway for coming soon models may vary by model. Taconic will confirm the applicable sourcing, availability, and delivery information during the quotation process.

Depending on the humanized target and model design, the portfolio may support evaluation of T-cell engagers, checkpoint-directed therapies, multispecific antibodies, Fc-engineered biologics, antibody-drug conjugates, pathway modulators, and other therapeutic approaches. Suitability depends on the therapeutic mechanism, target biology, intended readouts, and available model evidence.

Many models are maintained on immunocompetent C57BL/6 or BALB/c backgrounds and may be suitable for studies using background-compatible syngeneic tumor systems. Suitability depends on the specific model, tumor line, therapeutic mechanism, and experimental objective.

Models are provided for research use under the applicable terms and conditions. Breeding, cross-breeding, genetic modification, transfer, or other expanded uses are not authorized. Taconic will clarify the rights associated with the selected model during the ordering process.

Human target-expressing tumor cell lines are available for selected targets and may support certain model-plus-tumor-system strategies. Compatibility and study relevance should be evaluated for the specific mouse model, tumor line, therapeutic mechanism, and experimental objective.

Find a Humanized Model Aligned with Your Therapeutic Mechanism

Explore the available portfolio or register your interest to discuss model availability, biological fit, and ordering through Taconic in the United States.

Request Pricing and Availability—Discuss a Model with Taconic

Tell us which model or models are relevant to your program. A Taconic representative will follow up to discuss model availability and next steps.